EXAS - Exact Sciences Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
66.33
-2.49 (-3.62%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close68.82
Open68.99
Bid66.20 x 2200
Ask66.50 x 1300
Day's Range65.77 - 68.99
52 Week Range33.86 - 71.60
Volume3,779,393
Avg. Volume2,428,826
Market Cap8.085B
Beta1.09
PE Ratio (TTM)N/A
EPS (TTM)-1.00
Earnings DateJul 23, 2018 - Jul 27, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.10
Trade prices are not sourced from all markets
  • Investopedia3 days ago

    3 Small Cap Stocks That Can Thrive Amid a Trade War

    As concerns over trade wars escalate, investors may find refuge in small-cap stocks, which have been handily beating the broader market this year. Lower exposure to trade risk along with beneficial tax policy exposures, relative strength in U.S. economic growth, and potential merger activity, make small caps like GrubHub Inc. ( GRUB), Exact Sciences Corp. ( EXAS) and Aspen Technology Inc. ( AZPN), especially attractive in the current environment, according to CNBC.

  • PR Newswire5 days ago

    Cologuard Challenge Expands to AmFam Championship Urging PGA TOUR Champions Fans to Get Screened for Colon Cancer

    MADISON, Wis., June 19, 2018 /PRNewswire/ -- The national colon cancer screening movement led by golfer Jerry Kelly will be front and center when the PGA TOUR Champions comes to University Ridge Golf Course June 22-24, 2018 for the American Family Insurance Championship (AmFam Championship). Today, the American Family Insurance Championship and Exact Sciences announced an expanded partnership that makes the Madison-based company and its noninvasive colon cancer screening test, Cologuard, one of the leading partners of the 2018 event.

  • Benzinga5 days ago

    Benzinga's Daily Biotech Pulse: Biohaven Sells Right To Drug, Obseva To Sell Shares

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 18) Aptose Biosciences Inc (NASDAQ: APTO ) Arrowhead Pharmaceuticals ...

  • Benzinga16 days ago

    Benzinga's Daily Biotech Pulse: EDAP Device Gets FDA Nod, Ampliphi Presents Positive Data, Agile To Cut Jobs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Stocks hitting 52-week highs on June 7) Baxter International Inc (NYSE: BAX ) Bio-Rad Laboratories, ...

  • See what the IHS Markit Score report has to say about Exact Sciences Corp.
    Markit16 days ago

    See what the IHS Markit Score report has to say about Exact Sciences Corp.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • PR Newswire16 days ago

    Exact Sciences Announces Upsizing and Pricing of 1.0% Convertible Senior Notes Due 2025

    MADISON, Wis., June 8, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) announced today that it has priced its underwritten public offering of 1.0% Convertible Senior Notes due 2025 (the "Notes") and upsized the offering from $150 million to $190 million aggregate principal amount, providing for total gross proceeds of $202.4 million, excluding accrued interest.  The initial public offering price for the Notes will be 106.5% of face value plus accrued interest from January 17, 2018.  The Notes issuance is a reopening of, and will be fully fungible and form a single series with, the $690 million aggregate principal amount of the Company's 1.0% Convertible Senior Notes Due 2025 issued by the Company on January 17, 2018 and will have the same CUSIP number. The Company has granted the underwriters a 30-day option to purchase up to an additional $28.5 million aggregate principal amount of the Notes at the public offering price, less the underwriting discount, plus accrued interest.

  • PR Newswire17 days ago

    Exact Sciences Announces Offering of 1.0% Convertible Senior Notes Due 2025

    MADISON, Wis., June 7, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) today announced an underwritten public offering of $150 million aggregate principal amount of its 1.0% convertible senior notes due 2025 (the "Notes") in a registered public offering. The Company also plans to grant to the underwriters a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes at the public offering price, less the underwriting discount, plus accrued interest. The Notes issuance is a reopening of, and will be part of the same series as, the $690 million aggregate principal amount of 1.0% Convertible Senior Notes due 2025 issued by the Company on January 17, 2018.

  • This Biotech Said It Can Detect Liver Cancer In Your Blood — And Broke Out
    Investor's Business Daily18 days ago

    This Biotech Said It Can Detect Liver Cancer In Your Blood — And Broke Out

    Exact Sciences broke out to a record high Wednesday after the biotech showed its newest blood test could detect curable liver cancer in 91% of patients studied.

  • Benzinga18 days ago

    Benzinga's Daily Biotech Pulse: Vascular Biogenics Soars On Positive Platform Data, Axovant Licenses Parkinson's Candidate

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on June 5) Haemonetics Corporation (NYSE: HAE ) Athersys, Inc. (NASDAQ: ...

  • PR Newswire19 days ago

    Exact Sciences, Mayo Clinic Researchers Identify Blood-Based DNA Biomarker Panel to Accurately Diagnose Hepatocellular Carcinoma

    Data Presented at Digestive Disease Week Show Panel of Six Biomarkers is 95 Percent Sensitive for Most Common Type of Liver Cancer WASHINGTON , June 5, 2018 /PRNewswire/ -- Researchers at Exact Sciences ...

  • 20 Million More Potential Customers for Cologuard: Time to Buy Exact Sciences Stock?
    Motley Fool20 days ago

    20 Million More Potential Customers for Cologuard: Time to Buy Exact Sciences Stock?

    New guidelines mean new opportunities for Exact Sciences -- and maybe for investors, too.

  • ACCESSWIRE20 days ago

    Stock Performance Review on Exact Sciences and Three Other Medical Research Stocks

    Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).

  • Exact Sciences' Cologuard market expands by 20+ million with new American Cancer Society guidelines
    American City Business Journals23 days ago

    Exact Sciences' Cologuard market expands by 20+ million with new American Cancer Society guidelines

    Cologuard is currently available to individuals age 50 and older who are at average risk for colorectal cancer.

  • PR Newswire23 days ago

    Exact Sciences to participate in June investor conferences

    MADISON, Wis., June 1, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that company management will be presenting at the following investor conferences during June and invited investors to participate by webcast. The webcasts can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.

  • Why Movado Group, Fiat Chrysler Automobiles, and Exact Sciences Jumped Today
    Motley Fool25 days ago

    Why Movado Group, Fiat Chrysler Automobiles, and Exact Sciences Jumped Today

    Find out how a charitable organization helped lift one of these stocks.

  • Exact Sciences Applauds American Cancer Society's Updated Colorectal Cancer Screening Guidelines to Include People Age 45-49
    PR Newswire25 days ago

    Exact Sciences Applauds American Cancer Society's Updated Colorectal Cancer Screening Guidelines to Include People Age 45-49

    MADISON, Wis., May 30, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) strongly supports the American Cancer Society's (ACS) update to its colorectal cancer screening guidelines announced today. The new guidelines recommend colorectal cancer screening begin at age 45 for people at average risk of the disease.  With more than 20 million Americans age 45-49, Exact Sciences affirmed its commitment to seek U.S. Food and Drug Administration (FDA) approval for making Cologuard, its noninvasive colorectal cancer screening test, available to those in this population who are at average risk for colorectal cancer.

  • This News Explains Exact Sciences' Double-Digit Pop Today
    Motley Fool25 days ago

    This News Explains Exact Sciences' Double-Digit Pop Today

    Shares jump after the American Cancer Society tweaks its recommended guidelines for cancer screening. Here's what investors need to know.

  • Reuters25 days ago

    American Cancer Society recommends earlier colorectal cancer screening

    The American Cancer Society on Wednesday recommended that people at average risk of colorectal cancer start regular screening at the age of 45 rather than at 50, at a time when studies show a rise in cases of the disease among younger individuals. The new ACS guideline https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/acs-recommendations.html also recommends people, who are in good health and with a life expectancy of more than 10 years, should continue regular colorectal cancer screening through the age of 75. The guideline suggests screening either through a high sensitivity stool-based test or visual examination such as colonoscopy that snakes a tiny camera through the rectum to view the colon to search for abnormal tissue growth.

  • MarketWatch25 days ago

    Exact Sciences shares surge 11% on earlier cancer screening recommendation

    Exact Sciences Corp. , maker of a colon cancer test, had shares surge 11% in extremely heavy Wednesday trade after the American Cancer Society recommended screening for colon cancers starting five years earlier, at age 45.

  • Where Will Exact Sciences Corporation Be in 5 Years?
    Motley Fool26 days ago

    Where Will Exact Sciences Corporation Be in 5 Years?

    The Cologuard test is gaining popularity. Can it deliver profits?

  • Where Exact Sciences Corporation (NASDAQ:EXAS) Stands In Earnings Growth Against Its Industry
    Simply Wall St.last month

    Where Exact Sciences Corporation (NASDAQ:EXAS) Stands In Earnings Growth Against Its Industry

    After reading Exact Sciences Corporation’s (NASDAQ:EXAS) most recent earnings announcement (31 March 2018), I found it useful to look back at how the company has performed in the past andRead More...

  • Investopedialast month

    4 Biotech Stocks Set to Rise By 14% or More

    Biotech stocks are breaking out, with the SPDR S&P Biotech ETF ( XBI) gearing up for what could be a significant rise higher. Since that time the group has turned higher, and now technical analysis suggests more gains may lie ahead for the sector.

  • GlobeNewswire2 months ago

    Recent Analysis Shows Boardwalk Pipeline Partners, Chegg, CommScope Holding, Exact Sciences, HollyFrontier, and Hecla Mining Market Influences — Renewed Outlook, Key Drivers of Growth

    NEW YORK, May 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Boardwalk ...

  • Exact Sciences teams with Vince Lombardi foundation in fight against colon cancer
    American City Business Journals2 months ago

    Exact Sciences teams with Vince Lombardi foundation in fight against colon cancer

    The new partnership includes the organizations collaborating on national campaigns and donations made to the foundation from the medical device company.

  • Vince Lombardi Cancer Foundation and Exact Sciences Team Up to Fight Colon Cancer
    PR Newswire2 months ago

    Vince Lombardi Cancer Foundation and Exact Sciences Team Up to Fight Colon Cancer

    MILWAUKEE and MADISON, Wis., May 3, 2018 /PRNewswire/ -- Colon cancer cut short the life of legendary football coach Vince Lombardi at the age of 57 and, nearly 50 years later, remains the number two cancer killer in the United States. Now, the foundation bearing his name and one of the country's premier cancer diagnostics companies are teaming up to fight back. Today, the Vince Lombardi Cancer Foundation (VLCF) announced a new, multi-year partnership with Madison, Wis.-based Exact Sciences that will work to increase awareness of colon cancer, stress the importance of screening and prevention, and raise funds for cancer research.